Terms ending in 2035
Every in-force patent on Anavex Life Sciences Corp.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,441,563 | A 19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 10,813,907 | A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 11,690,821 | A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 12,594,256 | A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.